Morgan Stanley Maintains Overweight on Ingersoll Rand, Lowers Price Target to $52
Morgan Stanley analyst Joshua Pokrzywinski maintains Ingersoll Rand (NYSE:IR) with a Overweight and lowers the price target from $56 to $52.
Credit Suisse Maintains Neutral on Ingersoll Rand, Lowers Price Target to $52
Credit Suisse analyst John Walsh maintains Ingersoll Rand (NYSE:IR) with a Neutral and lowers the price target from $56 to $52.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Deutsche Bank Maintains Buy on Ingersoll Rand, Raises Price Target to $60
Deutsche Bank analyst Nicole Deblase maintains Ingersoll Rand (NYSE:IR) with a Buy and raises the price target from $58 to $60.
Wolfe Research Downgrades Ingersoll Rand to Peer Perform
Wolfe Research analyst Nigel Coe downgrades Ingersoll Rand (NYSE:IR) from Outperform to Peer Perform.
A Bearish Sign Appears On Ingersoll Rand’s Chart
If history is any guide, there may be trouble ahead for shares of Ingersoll Rand (NYSE:IR). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.